PROMOMED presented the first results of the "Start with Yourself" health support program for medical workers

PROMOMED presented the first results of the "Start with Yourself" pilot program aimed at preserving the metabolic health of medical workers. The project aims to reduce the risks of atherosclerosis, cardiovascular diseases and diabetes mellitus among representatives of this field. The social initiative was launched with the participation of Oksana Mikhailovna Drapkina, Chief freelance Specialist in Therapy and General Medical Practice at the Russian Ministry of Health, Honored Doctor of the Russian Federation, and is being implemented with the support of the Russian Ministry of Health.

Medical professionals often face negative factors such as stress and a sedentary lifestyle. Due to the high workload and focus on patients, they often postpone taking care of their own health. The "Start with Yourself" program demonstrates the effectiveness of an integrated approach, including drug treatment and regular monitoring of the condition by an endocrinologist. After the initial examination, each participant receives an individual therapy plan, and is also provided with the drug Velgia®[1] (INN semaglutide) from PROMOMED.

50 medical workers between the ages of 18 and 65 have become participants in the social initiative in the Republic of Mordovia. Most of them had concomitant diseases such as prediabetes or type 2 diabetes, hypertension, dyslipidemia, etc. The first results of the pilot project were published in the scientific journal Pharmacy and Pharmacology[2]. After 6 months of therapy, significant improvements were noted: the average decrease in body weight was 12 kg, body mass index — 4.33 kg/ m2; waist circumference decreased by 7.65 cm, hip circumference — by 9 cm. 4.2% of the participants reached a normal body weight. This allowed one in four of them to move from the obese category to the overweight category.

In addition, the medical staff recorded an improvement in the metabolic profile and a decrease in cardiovascular risk. Thus, the level of total cholesterol decreased by 8.27%, low-density lipoprotein cholesterol (a key risk factor for atherosclerosis and vascular disasters, in particular stroke and heart attack) — by 12.73%. The estimated 10-year cardiovascular risk on the SCORE2 scale decreased by 18.6%. At the same time, there was a decrease in uric acid and C-reactive protein levels, which indicates positive changes in the participants' health status.

The program was launched in May 2025. It is currently being implemented in the Republic of Mordovia, the Nizhny Novgorod Region and the Altai Territory. PROMOMED plans to expand the geography of the project to help as many medical professionals as possible improve their quality of life. The Company is convinced that receiving timely qualified assistance helps to improve the quality of healthcare in the country.

[1] This drug is a prescription drug and should only be purchased as prescribed by a doctor. The drug has contraindications. Please read the instructions for use. Do not use the drug unless it has been prescribed to you by your doctor. When using the drug, always follow the instructions for use and the recommendations of your doctor.

[2] Balykova L.A., Stolyarova V.V., Orlova D.A., Shokina S.V., Esina M.V., Yamashkina E.I., Surina T.A., Zorina L.A., Shcherbakova V.S., Zaslavskaya K.Ya., Bely P.A. Assessment of the effect of semaglutide on some cardiovascular risk factors in medical workers overweight or obese. The "Start with Yourself" program: a post-registration, single-center prospective study of routine clinical practice. Pharmacy and pharmacology. 2026;14(4):410-422. https://doi.org/10.19163/2307-9266-2026-14-4-410-422

Information about the Company
PROMOMED is a leading innovative biopharmaceutical company with significant growth potential in promising segments of the pharmaceutical market. PROMOMED celebrated its 20th anniversary in 2025. The ordinary shares of PJSC Promomed are traded on the Moscow Stock Exchange (ticker "PRMD").

The Company's structure includes its own unique world-class R&D center and a high—tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company is developing a diversified portfolio of more than 370 medicines in the top 10 segments of the pharmaceutical market. The Company's portfolio includes blockbuster drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of diseases in various therapeutic areas: endocrinology, oncology, neurology, autoimmune diseases, infection control, acute and chronic pain, and others. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.